Neoplasm Metastasis
Conditions
Keywords
Advanced skeletal metastases, Radium-223, Radium-223 dichloride, Alpharadin
Brief summary
A new bone-seeking radiopharmaceutical drug, called Radium-223 dichloride (formerly known as Alpharadin), is currently under development. It is an injectable aqueous solution containing radium-223, a radionuclide that emits radiation of another quality and with a different distribution than radiopharmaceuticals currently in use. After injection of the drug into the blood, a large portion of the drug will accumulate in the bones, and irradiate the skeletal metastases. The drug is expected to be retained longer in the painful sites of bone than in other sites of the body, and may alleviate pain through its radiation. Radium-223 is expected to be both efficacious as regards the targeted localised irradiation, and also to have a favourable safety profile. The radiopharmaceutical drug Radium-223 has not been given to humans before. In this first clinical study in man, a so-called phase I study, the safety, tolerance and the toxicity of various radioactivity doses of Radium-223 will be evaluated.
Interventions
RADIATIONRadium-223 dichloride (BAY88-8223)
\- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
Sponsors
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 30 years of age * has histologically or cytologically confirmed breast or prostate carcinoma * presents with bony metastases, confirmed by scintigraphic imaging within the previous 4 weeks * relapsing with new foci in the skeleton after previous external radiotherapy * has a life expectancy of at least 8 weeks (study part Ia), 5 months for study part Ib * good performance status; ECOG (Eastern Cooperative Oncology Group) status 0-2 * has normal bone marrow, hepatic, renal and cardiac functions * clinical chemical laboratory values are within pre-specified range, measured within 7 days prior to dosing day * for female patients: post-menopausal, surgically sterile or taking adequate contraceptive precaution
Exclusion criteria
* has previously been included in this study. This criterion is applicable for patients that receive a single injection of the study drug, but not for patients to be re-treated, or for those to receive a fractionated dosing regimen (study part Ib). * has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration. This criterion is applicable for patients that receive a single injection of the study drug and for patients to be re-treated. * has received any other investigational drug than radium-223 in the 4 weeks before first injection of study drug or is scheduled to receiving one during or in the 8 weeks after the fractionated study drug regimen. This criterion is applicable for patients receiving fractionated dose of the study drug. * has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study * has other active, serious, life-threatening disease with a life expectancy of less than 8 weeks * has any uncontrolled infection * requires oxygen for pulmonary metastases * has poor renal function with S-Creatinine \>150 mmol/L (males), \>100 mmol/L (females) * has heart insufficiency, Class III or IV NYHA (New York Heart Association) * is pregnant or lactating * for female patients: of childbearing potential, and not taking adequate contraceptive measures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with predetermined adverse events (dose limiting toxicity [DLT]) as a measure of safety and tolerability while dose escalating | Up to 8 weeks from injection |
Secondary
| Measure | Time frame |
|---|---|
| Blood clearance of radioactivity | 48 hours after the last injection |
| Quality of Life Questionnaire | 8 weeks after the last injection |
Countries
Norway, Sweden
Outcome results
None listed